In Belgium, the biotechnology companies VIRCO and TIBOTEC are considering merging, creating a new entity which will concentrate the parties activities and which will be specialised in the treatment of AIDS, infectious diseases and oncology. It will be 65% held by TIBOTEC and 35% by VIRCO.